News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG Molecular Diagnostics and Firalis Announce an Agreement Enabling Firalis’ Commercialization of Theranostic and Research Products and Services Based on HTG EdgeSeq Technology
TUCSON, Ariz. and HUNINGUE, France , May 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based
View HTML
Toggle Summary HTG Molecular Diagnostics to Announce First Quarter Financial Results and Host Conference Call on Thursday, May 10
TUCSON, Ariz. , April 27, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the quarter ended March 31, 2018 after the market
View HTML
Toggle Summary HTG Promotes John Lubniewski to President and Chief Operating Officer
Mr. Lubniewski assumes the role after having served for seven years as Chief Business Officer TUCSON, Ariz. , April 16, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the
View HTML
Toggle Summary HTG Announces New Patent for Its Technology Issued in Japan
Patent covers nuclease protection methods for detection of nucleotide variants   TUCSON, Ariz. , April 03, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the issuance of
View HTML
Toggle Summary HTG Molecular Diagnostics Secures Debt Facility with MidCap Financial
TUCSON, Ariz. , March 27, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications today announced that it has entered into a senior debt facility with MidCap Financial (MidCap), a healthcare
View HTML
Toggle Summary HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2017 Results
Revenue increased 442% and 188%, respectively, compared to the three and twelve month periods in the prior year driven by development efforts supporting Pharma clinical programs TUCSON, Ariz. , March 22, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
View HTML
Toggle Summary HTG Molecular Diagnostics to Announce Fourth Quarter and Year-End Financial Results and Host Conference Call on Thursday, March 22
TUCSON, Ariz. , March 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the quarter and year ended December 31, 2017 after
View HTML
Toggle Summary HTG Announces New Australian Patent for Its Technology
Patent covers methods of co-detecting mRNA and small non-coding RNA TUCSON, Ariz. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the issuance of Australian
View HTML
Toggle Summary HTG Molecular Diagnostics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
TUCSON, Ariz. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced that management will present in a fireside chat at the LEERINK Partners 7th Annual Global
View HTML
Toggle Summary HTG Molecular Diagnostics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
TUCSON, Ariz. , Jan. 23, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced the completion of its previously announced underwritten public offering of 13,915,000 shares
View HTML